Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control.
about
TMC207: the first compound of a new class of potent anti-tuberculosis drugsThe mechanism of action of PA-824: Novel insights from transcriptional profilingPA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO releaseTargeting the chromosome partitioning protein ParA in tuberculosis drug discoveryMycobacterium tuberculosis MT2816 encodes a key stress-response regulatorFunctional genomics reveals extended roles of the Mycobacterium tuberculosis stress response factor sigmaHAggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortalityCost-effectiveness comparison of Genechip and conventional drug susceptibility test for detecting multidrug-resistant tuberculosis in ChinaBibliometric analysis of worldwide publications on multi-, extensively, and totally drug - resistant tuberculosis (2006-2015)A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsNovel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosisEpidemiology and treatment of multidrug resistant tuberculosisGenetic variation of Mycobacterium tuberculosis circulating in Kharkiv Oblast, Ukraine.Endophytic Streptomyces sp. Y3111 from traditional Chinese medicine produced antitubercular pluramycins.Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.Comparison of the mycobacterium growth indicator tube method and the method of proportion for drug susceptibility testing of mycobacterium tuberculosisDiagnostic value of GeneChip for detection of resistant Mycobacterium tuberculosis in patients with differing treatment historiesImmunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapyNew drugs to treat tuberculosis.Confronting the scientific obstacles to global control of tuberculosis.Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges.Multicenter evaluation of genechip for detection of multidrug-resistant Mycobacterium tuberculosis.Mycobacterium tuberculosis Rv1152 is a Novel GntR Family Transcriptional Regulator Involved in Intrinsic Vancomycin Resistance and is a Potential Vancomycin Adjuvant TargetThe TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics.Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosisExtensively drug-resistant tuberculosis: current challenges and threats.Comprehensive treatment of extensively drug-resistant tuberculosis.Economics of antibiotic resistance.Synthesis of deoxygenated alpha(1-->5)-linked arabinofuranose disaccharides as substrates and inhibitors of arabinosyltransferases of Mycobacterium tuberculosisStructure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships.Tuberculosis vaccines: present and future.Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.Clinical evolution of a group of patients with multidrug-resistant TB treated at a referral center in the city of Rio de Janeiro, Brazil.Multidrug- and extensively drug-resistant TB in persons living with HIV.Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance SurveySynthesis, structure, and tuberculostatic activity of dimethyl benzoylcarbonohydrazonodithioates.Expression, purification and preliminary crystallographic analysis of N-acetylglucosamine-1-phosphate uridylyltransferase from Mycobacterium tuberculosis.Patients with multidrug-resistant tuberculosis display impaired Th1 responses and enhanced regulatory T-cell levels in response to an outbreak of multidrug-resistant Mycobacterium tuberculosis M and Ra strains.After 40 years, new medicine for combating TB.In-house, simple & economical phage technique for rapid detection of rifampicin, isoniazid, ethambutol, streptomycin & ciprofloxacin drug resistance using Mycobacterium tuberculosis isolates.
P2860
Q24632091-E8D63292-36C0-4E01-85D1-4E7149BB9F31Q24643238-3E3327D6-81B3-49D5-AC65-55A8487D6468Q24654913-236800A9-1AAE-4DF4-888D-E1712AC4940FQ28486773-BF557ED5-E6E0-44AB-A4E6-833B7EC3CCB0Q28487103-14F80E7C-DE0C-4568-8AF1-44D9ED8AF882Q28487106-FA91BD88-50C5-4791-BC16-2C52BEB313D1Q28487938-23384FE6-0DBE-4513-ABC8-022FFFF7128AQ28534773-879BFF09-8184-4418-9FB4-E94BA9C274B6Q28555235-9F7A1BB4-5137-42B3-877E-AFFFF2605689Q28742450-03865803-D1F8-4C42-A6BC-D5B3422231B2Q28830471-8830C30C-8821-4E62-998C-51F17057678AQ33710690-CFC445D2-7D8D-4ADC-A80A-E1D3A2FD9F6DQ33856525-265F8380-86B9-4AFF-B130-43ECBC390406Q34382525-85FAC765-D4EB-491B-8F48-BC85994274E0Q34410451-73A6BA88-4F2E-4DCA-A172-7A731DEA64C5Q34666985-0D006444-E631-4C54-AD2E-A7DCD89C9A54Q34916301-754FBC8D-9DA0-42BF-BF9D-FD9F6602982CQ35124651-E561A9B4-C643-415E-A43E-D379FFB54639Q36018409-CA3C2573-0C6E-41BE-A5CF-13453506A559Q36513366-93E07D63-19EA-4628-844D-E08893340825Q37021335-7CDCF8C3-B10C-48D9-A72E-0B317923B958Q37026454-5DDE8512-969B-4E8C-B3B9-2D69458016ABQ37044428-1E17E26A-F091-44BB-8AC6-DFD12C3ACA90Q37119027-1821290C-B1FD-4415-B619-9715DF02DF91Q37120065-AF209F8C-A1E9-4EC3-8B8C-D11034185064Q37163527-CC3CBA4C-925F-430C-8A02-363D28A85D6BQ37170546-FDD507B5-AE8A-4EEB-AAB8-55A51A9E490FQ37228745-6D068137-CA3D-4098-9553-F9062E434C44Q37254836-C7121744-AA9D-4A63-A813-A3A9AA71F6C2Q37395782-18DD4574-8667-4723-8AB3-378623CD786AQ37754908-0FB569DC-3598-434B-AE28-12D46ADCB6C6Q39152809-4518D176-801B-4D16-9B7B-74A5448F6236Q39209744-F00875F5-7B16-494B-BA94-6266EA0F70D9Q39226104-8B86C7E0-8700-42C3-8363-AC9D7DB70512Q40794905-E2273DF7-9FC5-49B2-84BF-C9079DFF6088Q41269321-A67995F7-AEA1-414C-9147-4EC8215A8A53Q41828790-B5A793A8-6DE0-43ED-8414-6E404924FA5AQ41961229-741045A7-7318-4539-A284-B3926D747E11Q42119482-C1CBE8B3-126E-40DF-B156-727B87A050EBQ42244592-3615559C-30FB-4D51-890A-D2F61C82074F
P2860
Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Multidrug-resistant and extens ...... sis: epidemiology and control.
@en
type
label
Multidrug-resistant and extens ...... sis: epidemiology and control.
@en
prefLabel
Multidrug-resistant and extens ...... sis: epidemiology and control.
@en
P2860
P50
P356
P1476
Multidrug-resistant and extens ...... osis: epidemiology and control
@en
P2093
Daniela Cirillo
Enrico Girard
P2860
P304
P356
10.1586/14787210.5.5.857
P577
2007-10-01T00:00:00Z